Phase 2 Kidney Cancer Trial, Recruiting NCT07037004 Sponsor: City of Hope Medical Center Condition: Kidney Cancer
Back to Kidney Cancer

Phase 2 Kidney Cancer Trial, Recruiting

NCT07037004
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to give your informed consent to take part in the trial
  • Your kidney cancer has been confirmed by a tissue sample (biopsy) and is a specific type called clear-cell or sarcomatoid renal cell carcinoma
  • Your cancer is at a certain stage or spread, as determined by your medical team after surgery (confirm with trial site for exact staging details)
  • You have never had immunotherapy treatment for your kidney cancer before
  • You are generally able to carry out daily activities with little to no limitation (confirm with trial site)
  • You are 18 years of age or older
  • You are of any ethnic or racial background
  • Your kidneys and liver are functioning well enough, based on standard blood tests
  • Your bone marrow is producing enough blood cells, based on standard blood tests
  • If you are a woman who could become pregnant, or the female partner of a male participant, you must agree to use a reliable form of contraception during treatment and for at least 5 months after the last dose

Who may not be able to join:

  • You have previously had radiation therapy or certain immunotherapy drugs (anti-PD1, anti-PDL1, or anti-CTLA-4) for kidney cancer
  • You have an active or recent autoimmune disease, or have needed steroid or immune-suppressing medications for such a condition (some exceptions may apply — confirm with trial site)
  • You have active lung inflammation (such as a condition called pneumonitis) or have had it in the past and needed steroid treatment
  • Your blood oxygen level is below 92% while breathing normal room air
  • You are currently using or plan to use probiotics, prebiotics, yogurt, bacteria-enriched foods, or similar supplements within 2 weeks before or during treatment
  • You are currently taking steroid medications above a certain dose, or other immune-suppressing medicines, within 14 days before starting the trial (some exceptions may apply — confirm with trial site)
  • You have uncontrolled adrenal gland problems
  • You have a medical condition — such as ongoing diarrhoea or a bowel condition — that the trial doctor believes could make participation unsafe or affect results
  • You still have significant side effects from any previous treatment that have not yet resolved
  • You are currently pregnant or breastfeeding
  • You have a history of heart muscle inflammation, serious heart failure, unstable chest pain, serious uncontrolled heart rhythm problems, uncontrolled infection, or a heart attack within the past 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2027
Est. completion
24 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in interleukin (IL)-12 levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov